Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles


Neng-Yao Shih, Ph.D.

Associate Investigator
National Institute of Cancer Research
jshih@nhri.org.tw

EDUCATION

Ph.D., Molecular and Cell Biology Program, Arizona State University, USA, 1996
M.S., Biology, Tunghai University, Taiwan, 1984
B.S., Biology, Tunghai University, Taiwan, 1982

PROFESSIONAL EXPERIENCES

- Assistant Investigator, National Institute of Cancer Research, National Health Research Institutes, Taiwan (2001-present)
- Instructor, Immunology Program/Department of Pathology, Washington University, St. Louis, Missouri, USA (2000-2001)
- Postdoctoral Fellow, Immunology Program/Department of Pathology, Washington University, St. Louis, Missouri, U.S.A. (1997-1999)
- Research Associate, Department of Zoology, Arizona State University, Tempe, Arizona, U.S.A. (1992-1996)
- Associate Scientist, Cell Biology and Immunology Division, Development Center of Biotechnology (DCB), Taiwan (1989-1991)

RESEARCH INTERESTS

Dr. Shih's research is mainly focused on how tumor cells escape from the immune attack and what the molecular mechanisms mediated by the tumor cells are. Three major research directions are undergoing in his lab: (1) cloning of genes encoding “immunogenic” tumor-associated antigens (TAAs), those are recognized by immune cells, from patients with lung or ovarian cancer; (2) functional studies of those TAAs in tumor cells and in tumor surveillance, primarily, focused on how tumor cells mediate TAAs to induce immune suppression or tolerance; (3) therapeutic effects of the TAAs in tumor prevention and eradication. In addition, his lab is also interested in functional dysregulation of cytotoxic T lymphocytes (Tc) and T regulator (Treg) in cancer patients by examining activation status of signaling molecules. Currently, several tumor-associated genes have been identified and characterized as novel clinical prognostic and diagnostic markers for lung and ovarian cancers. Results from molecular dissection of several TAAs functioning in tumor cells also strongly supports their roles on tumor malignancy. Using those TAAs as vaccine antigens in animal model, his lab preliminarily conformed their therapeutic effects on tumor prevention and eradication.

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

Dr. Shih has successfully cloned and identified several genes coding for immunogenic tumor-associated antigens using either a combination of biochemical purification and mass spectrometric analyses or peptide-displaying system. Expression statuses of those antigens have been confirmed to be tightly associated with clinical outcomes, including total disease-free and metastasis-free survivals, in patients with either lung or ovarian cancer. They also further characterized the cellular functions of these antigens in tumor cells. For instance, overexpression of the p48ENO1 gene in noninvasive cells could significantly increase cell migration and enhance lung metastasis in animals. The molecular mechanisms associated with this biological behavior are mediated by upregulation of some chemokines and cytoskeleton proteins in the cells. Intriguingly, using P48ENO1 as a target of immune attack, they successfully demonstrated that induction of anti-ENO1 immunity was sufficient to prevent and suppress tumor growth in immunocompetent mice. This work has been filed US and Taiwan patents and published in an international journal. Additionally, this funding can provide not only alternative cancer treatment for cancer patients, but also a novel potential tumor marker for prognosis of lung cancer.

HONORS & AWARDS

1. Member in Who and Who in Science (2000-present)
2. Honor Member in the Honor Society of Phi Kappa Phi, USA (1994 -present)
3. Dissertation Research Assistantship Award (1995)
4. MCB Research Assistantship Award (1993-1994)
5. Graduate Academic Scholarship (1991)
6. Sino-American Academic Scholarship (1981-1982)
7. Chungcheng Academic Scholarship (1981)

SELECTED PUBLICATIONS

  1. Chen KL, Liu WH, Yang YY, Leu SJC and ShihNY. Characterization of novel transforming growth factor-beta type I receptors found in malignant pleural effusion tumor cells. BMC Mole Biol, 8:72, 2007.

  2. Lee YC, Leu SJC, Hu CJ, ShihNY, Huang IJ, Wu HH, Hsieh WS, Chiang BL, Chui WT, and Yang YY. (2007). Chicken variable-chain fragment against the SARS-CoV spike protein. J Virology Methods, 146:104, 2007.

  3. Liu K and ShihNY. The role of enolase in tissue invasion and metastasis of pathogens and tumor cells. J Cancer Mol, 3:45, 2007.

  4. Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S,Liu HK, Luh KT, Hsu LH, Wu CW, Chen CY, Chen KC, Yang TY, Chou TY, Wang WH, Whang-Peng J and Shih NY. Identification of ?-enolase as an autoantigen in lung cancer: its overexpression is tightly correlated with clinical outcomes. Clin. Cancer Res, 12(19):5746, 2006.

  5. Shih NY, Li J, Cotran R, Mundel P, Miner JH, and ShawAS. CD2AP localizes to the slit diaphragm and binds to nephrin via a novel C-terminal domain. Am J Pathol, 159(6):2303, 2001.

  6. Shih NY, Li J, Miner JH, and ShawAS. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science, 286:312, 1999.

  7. Shih NY, Soesilo I and Floyd-Smith G. Stabilization of Invariant chain mRNA by 12-O-tetradecanoylphorbol-13-acetate is blocked by IFN-? in a murine B lymphoma cell line. J. Interferon and Cytokine Res, 17:747, 1997.

PATENT

USA; US Prevision Patent "Alpha-enolase specific antibody and method of use"; 2005.